Skip Navigation Links

Benjamin Pollock, PhD, MSPH, CPH

Benjamin Pollock


Dr. Pollock is an Epidemiologist for the Epidemiology Department at Baylor Scott & White Health. He received his PhD with a focus on cardiovascular epidemiology at Tulane University. He received his Master's of Science in Public Health from the Johns Hopkins Bloomberg School of Public Health, where he also received a certificate in Risk Sciences and Public Policy. He obtained a Bachelor's of Science degree in Biology from the University of Akron.


Dr. Pollock completed the Epidemiology Department research internship, and works on data analysis and manuscript preparation for several of Dr. Filardo's funded research projects, including the multicenter NHLBI-funded R01 grant (1R01HL103683) studying new-onset atrial fibrillation after isolated CABG surgery and Gilead Sciences (IN-US-259-1332) investigating the effectiveness of ranolazine in reducing post-PCI hospital re-admission. He is skilled in data analysis, risk-adjustment, and statistical modeling.  


Publications on ResearchGate through PubMed


Ongoing Research Support



All of Us Research Program


This large epidemiologic study seeks to establish a national research cohort of 1 million participants within which research at the intersection of human biology, behavior, genetics, environment, data science and computation, and much more will be conducted with the goal of developing more effective ways to prolong health and treat disease.


Role: Epidemiologist

Amount: $1,800,000



Gilead Sciences 


Effectiveness of ranolazine at admission and/or discharge in reducing re-admissions after PCI 


Of the ~1.5 million people who undergo diagnostic cardiac catheterization or percutaneous coronary intervention (PCI) every year in the United States, 9-16% are re-admitted within 30 days, and these patients are at high risk of dying or suffering a heart attack or stroke within 1 year. Ranolazine is currently used to treat angina, but that also has anti-arrhythmic and anti-inflammatory effects. As such, it may prevent some of the complications that develop after cardiac catheterization/PCI, reducing patients’ need to be re-admitted and their costs of care. This population-based, multi-site observational study investigates ranolazine’s potential to prevent short- and long-term re-hospitalizations after cardiac catheterization/PCI, and the associated impact on costs of care.

ranolazine as a prophylactic and/or therapeutic agent. 

Role: Health Care Researcher

Amount: $492,000 



NIH/National Heart Lung Blood Institute (R01HL103683)


New-onset Post-CABG Atrial Fibrillation


This is a large multicenter observational study which includes 32,420 consecutive patients without pre-operative AF who underwent isolated CABG between 1/1/1997 and 12/31/2008 at Baylor University Medical Center (Dallas, TX), Emory University (Atlanta, GA), University of Virginia (Charlottesville, VA) and Washington University (St. Louis, MO) using data from the STS database, patient medical records, administrative data, and the Social Security Administration Death Master File. The study seeks to evaluate the effectiveness of the prophylaxis and management strategies for new-onset AF following isolated CABG and their impact on long-term survival (>15 years).


Role: Health Care Researcher

Amount: $2,330,042



Discovery Foundation


New-onset post-CABG Atrial fibrillation and survival in women


This is a retrospective population-based multicenter study assessing the effectiveness of optimal preventive and management strategies and their impact on incidence of new-onset post-CABG atrial fibrillation and long-term survival in women.

Role: Health Care Researcher

Amount: $99,695



Baylor Foundation and Baylor Heart and Vascular Institute


The rose of established pre-operative risk factors in predicting long-term survival in patients undergoing cardiac surgery: Risk models


This study builds predictive models to accurately estimate patients’ risk for long-term adverse events following coronary artery bypass graft (CABG) and other cardiac surgeries. Primary outcomes of interest are: mortality (operative and in-hospital), stroke, acute renal failure, deep sternal wound infection, re-operation, and prolonged ventilation.


The study will also assess differences between hybrid revascularization strategies (concomitant revascularization versus staged approach – with PCI coming before or after surgery) and renal failure and bleeding, evaluate and characterize each coronary lesion to determine if these lesions were optimal for the hybrid approach, or if they affected the need for repeat revascularization, and utilize the results of the study to create a registry moving forward to serve as the basis for a prospective evaluation of hybrid revascularization.


Role: Health Care Researcher

Amount: $37,800



Copyright © 2015 Baylor Scott & White Health All Rights Reserved.   |   3500 Gaston Avenue, Dallas, TX 75246-2017   |   1.800.9BAYLOR
Site Map   |   Privacy Terms & Patient Rights   |   Terms of Use